PT3642242T - Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas - Google Patents

Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas

Info

Publication number
PT3642242T
PT3642242T PT188200117T PT18820011T PT3642242T PT 3642242 T PT3642242 T PT 3642242T PT 188200117 T PT188200117 T PT 188200117T PT 18820011 T PT18820011 T PT 18820011T PT 3642242 T PT3642242 T PT 3642242T
Authority
PT
Portugal
Prior art keywords
hematologic malignancies
dosing parameters
targeting therapies
therapies
targeting
Prior art date
Application number
PT188200117T
Other languages
English (en)
Original Assignee
Univ Leland Stanford Junior
Forty Seven Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Forty Seven Inc filed Critical Univ Leland Stanford Junior
Publication of PT3642242T publication Critical patent/PT3642242T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT188200117T 2017-06-21 2018-06-21 Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas PT3642242T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762523182P 2017-06-21 2017-06-21

Publications (1)

Publication Number Publication Date
PT3642242T true PT3642242T (pt) 2024-04-16

Family

ID=64735831

Family Applications (1)

Application Number Title Priority Date Filing Date
PT188200117T PT3642242T (pt) 2017-06-21 2018-06-21 Parâmetros de dosagem para terapias de direcionamento de cd47 para malignidades hematológicas

Country Status (11)

Country Link
US (3) US11141480B2 (pt)
EP (2) EP3642242B1 (pt)
JP (2) JP7312706B2 (pt)
KR (1) KR20200019619A (pt)
CN (2) CN117065013A (pt)
AU (1) AU2018290248A1 (pt)
CA (1) CA3063099A1 (pt)
PL (1) PL3642242T3 (pt)
PT (1) PT3642242T (pt)
SI (1) SI3642242T1 (pt)
WO (1) WO2018237168A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2796085T3 (es) 2008-01-15 2020-11-25 Univ Leland Stanford Junior Marcadores de células madre de leucemia mieloide aguda
US11072655B2 (en) * 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
US11141480B2 (en) * 2017-06-21 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for CD47 targeting therapies to hematologic malignancies
EP3817773A4 (en) 2018-11-26 2021-09-15 Forty Seven, Inc. HUMANIZED ANTIBODIES AGAINST C-KIT
MA56119A (fr) 2019-06-07 2022-04-13 Alx Oncology Inc Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques
TW202124450A (zh) * 2019-10-18 2021-07-01 美商四十七股份有限公司 用於治療骨髓發育不良症候群及急性骨髓白血病之組合療法
CA3162633A1 (en) * 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
CN111905101B (zh) * 2020-07-03 2022-09-23 中山大学 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其***的方法
WO2022007947A1 (zh) * 2020-07-10 2022-01-13 信达生物制药(苏州)有限公司 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途
JP2023552375A (ja) 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための多量体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027428A1 (en) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
PT3056514T (pt) * 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação de fagocitose mediada por cd47
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US8758750B2 (en) * 2009-09-15 2014-06-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
DK2804617T3 (da) 2012-01-17 2020-08-10 Univ Leland Stanford Junior Højaffine sirp-alpha-reagenser
DK2970493T3 (da) * 2013-03-15 2019-05-13 Univ Leland Stanford Junior Fremgangsmåder til opnåelse af terapeutisk effektive doser af anti-cd47-midler
WO2015041987A1 (en) 2013-09-18 2015-03-26 The Board Of Trustees Of The Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
KR102271434B1 (ko) 2014-09-26 2021-07-01 엘지전자 주식회사 이동단말기 및 그 제어방법
US20180127829A1 (en) 2014-12-10 2018-05-10 Board Of Regents, The University Of Texas System Circulating tumor and tumor stem cell detection using genomic specific probes
GB2558131B (en) * 2015-09-21 2021-05-19 Surface Oncology Inc Anti-CD47 antibodies and methods of use
US11141480B2 (en) * 2017-06-21 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for CD47 targeting therapies to hematologic malignancies

Also Published As

Publication number Publication date
US20210401979A1 (en) 2021-12-30
WO2018237168A1 (en) 2018-12-27
AU2018290248A1 (en) 2019-11-28
US20230270852A1 (en) 2023-08-31
EP3642242A1 (en) 2020-04-29
CN110831974B (zh) 2024-05-14
CN110831974A (zh) 2020-02-21
US11141480B2 (en) 2021-10-12
JP2023083424A (ja) 2023-06-15
US20200147212A1 (en) 2020-05-14
JP2020525435A (ja) 2020-08-27
PL3642242T3 (pl) 2024-05-27
EP3642242A4 (en) 2021-06-23
EP4368206A2 (en) 2024-05-15
CA3063099A1 (en) 2018-12-27
SI3642242T1 (sl) 2024-05-31
CN117065013A (zh) 2023-11-17
JP7312706B2 (ja) 2023-07-21
EP3642242B1 (en) 2024-02-07
KR20200019619A (ko) 2020-02-24

Similar Documents

Publication Publication Date Title
SI3642242T1 (sl) Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti
HK1223552A1 (zh) 用於癌症的組合療法
HK1223402A1 (zh) 免疫溶瘤療法
IL247306A0 (en) Specific antibody modification sites to create immunoconjugates
IL247566A0 (en) Routine payments to payment coordinators
ZA201902009B (en) Anti-folr1 immunocunjugate dosing regimens
PL3177547T3 (pl) Opakowanie do papierosów
PL3243767T3 (pl) Paczka na papierosy
PL3347054T3 (pl) Schematy dawkowania koniugatów przeciwciało anty-TF-lek
HK1259491A1 (zh) 給藥方案
HK1245120A1 (zh) 用於癌症的新治療
HK1212713A1 (zh) 抗體的治療性用途
IL251870A0 (en) Dosing regimens of buprenorphine
SG11201700967RA (en) Container with wrapper with removable portion
HUE045254T2 (hu) Eljárások kipufogódobok szálasanyaggal történõ megtöltésére
PL2905242T3 (pl) Opakowanie na papierosy
HK1203186A1 (en) Ground conveying machine
HK1211301A1 (en) Anti-mcsp antibodies mcsp
GB201421869D0 (en) SCR dosing system
GB201510046D0 (en) Chordal - automatic harmonizer for melody
HUE038851T2 (hu) Dohánytasak
TWM476459U (en) Fertilizer dispensing machine
GB201415253D0 (en) Tobacco pouch
EP2983540A4 (en) VIBRANT SHOES